Levi & Korsinsky Files Class Action Lawsuit Against Zenas BioPharma, Inc.
Levi & Korsinsky, LLP, a prominent securities litigation firm, has announced the filing of a class action securities lawsuit against Zenas BioPharma, Inc. (NASDAQ: ZBIO), following concerns about the company’s initial public offering (IPO) in September 2024.
The class action lawsuit targets investors who bought Zenas BioPharma securities during the September 2024 IPO.
The complaint alleges that the company and certain individuals made misleading statements about the sustainability of its cash reserves, including the funds raised through the IPO.
Specifically, Zenas BioPharma is accused of overstating how long its existing cash, including IPO proceeds, would support its operations.
The lawsuit claims that the defendants made negligent and false public statements, which could have influenced investors’ decisions and led to financial losses.
If you purchased or acquired Zenas BioPharma securities between the IPO date and now, you may be eligible to join the lawsuit.
You can participate either by applying to become the lead plaintiff or by joining the class action without serving in a leadership role.
If you’re interested in taking a more active role, the deadline for submitting a lead plaintiff application is June 16, 2025.
Levi & Korsinsky, LLP encourages affected investors to learn more about their rights by filling out the case submission form available on their website. For additional information, you can contact Joseph E. Levi, Esq. directly at jlevi@levikorsinsky.com or call (212) 363-7500.
There’s no cost to join the class action. Legal fees are generally covered by any recovery from the lawsuit, so you won’t need to pay anything upfront. This allows investors to seek potential compensation without bearing any initial financial burden.
Time is of the essence for investors looking to protect their rights and seek compensation. Acting now ensures that your interests are represented in this important case. Visit the lawsuit page or reach out to Levi & Korsinsky, LLP today for more details.
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Their lead product, obexelimab, targets CD19 and FcγRIIb to regulate B cell activity in diseases like Immunoglobulin G4-Related Disease, relapsing multiple sclerosis, and lupus. Zenas aims to improve patient lives with innovative treatments, guided by core values of Transparency, Relationships, Excellence, Urgency, and Innovation. Led by a seasoned executive team, the company fosters a collaborative, diverse, and dynamic culture focused on impactful results.
Levi & Korsinsky LLP is a recognized leader in securities litigation, with a track record of recovering hundreds of millions of dollars for shareholders over the past two decades. With a dedicated team of over 70 professionals, the firm specializes in complex securities cases and has been featured in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years.
